Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Beam Therapeutics Inc.

    NASDAQ: BEAM · Real-Time Price · USD
    16.80
    -0.34 (-1.98%)
    At close: Jun 27, 2025, 3:59 PM
    16.93
    0.74%
    After-hours: Jun 27, 2025, 05:54 PM EDT

    Beam Therapeutics Statistics

    Share Statistics

    Beam Therapeutics has 100.56M shares outstanding. The number of shares has increased by 21.3% in one year.

    Shares Outstanding

    n/a
    		 100.56M

    Shares Change (YoY)

    n/a
    		 21.3%

    Shares Change (QoQ)

    n/a
    		 20.57%

    Owned by Institutions (%)

    n/a
    		 98.88%

    Shares Floating

    n/a
    		 89.62M

    Failed to Deliver (FTD) Shares

    n/a
    		 2,287

    FTD / Avg. Volume

    n/a
    		 0.1%

    Short Selling Information

    The latest short interest is 21.16M, so 21.04% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 21.16M

    Short % of Shares Out

    n/a
    		 21.04%

    Short % of Float

    n/a
    		 23.66%

    Short Ratio (days to cover)

    n/a
    		 13.65

    Valuation Ratios

    The PE ratio is -5.42 and the forward PE ratio is -3.62. Beam Therapeutics's PEG ratio is -0.03.

    PE Ratio

    n/a
    		 -5.42

    Forward PE

    n/a
    		 -3.62

    PS Ratio

    n/a
    		 32.14

    Forward PS

    n/a
    		 3.6

    PB Ratio

    n/a
    		 2.78

    P/FCF Ratio

    n/a
    		 -5.73

    PEG Ratio

    n/a
    		 -0.03
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Beam Therapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 4.82, with a Debt / Equity ratio of 0.22.

    Current Ratio

    n/a
    		 4.82

    Quick Ratio

    n/a
    		 4.82

    Debt / Equity

    n/a
    		 0.22

    Debt / EBITDA

    n/a
    		 -0.42

    Debt / FCF

    n/a
    		 -0.45

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $161,623.41

    Profits Per Employee

    n/a
    		 $-958,631.04

    Employee Count

    n/a
    		 393

    Asset Turnover

    n/a
    		 0.06

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 39K

    Effective Tax Rate

    n/a
    		 -0.01%

    Stock Price Statistics

    The stock price has increased by -28.4% in the last 52 weeks. The beta is 2.08, so Beam Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 2.08

    52-Week Price Change

    n/a
    		 -28.4%

    50-Day Moving Average

    n/a
    		 17.69

    200-Day Moving Average

    n/a
    		 23.25

    Relative Strength Index (RSI)

    n/a
    		 48.68

    Average Volume (20 Days)

    n/a
    		 2,234,945

    Income Statement

    In the last 12 months, Beam Therapeutics had revenue of 63.52M and earned -376.74M in profits. Earnings per share was -4.58.

    Revenue

    n/a
    		 63.52M

    Gross Profit

    n/a
    		 41.59M

    Operating Income

    n/a
    		 -415.57M

    Net Income

    n/a
    		 -376.74M

    EBITDA

    n/a
    		 -383.98M

    EBIT

    n/a
    		 -415.57M

    Earnings Per Share (EPS)

    n/a
    		 -4.58
    Full Income Statement

    Balance Sheet

    The company has 281.97M in cash and 161.43M in debt, giving a net cash position of 120.54M.

    Cash & Cash Equivalents

    n/a
    		 281.97M

    Total Debt

    n/a
    		 161.43M

    Net Cash

    n/a
    		 120.54M

    Retained Earnings

    n/a
    		 -1.57B

    Total Assets

    n/a
    		 1.47B

    Working Capital

    n/a
    		 1.11B
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -347.25M and capital expenditures -8.95M, giving a free cash flow of -356.19M.

    Operating Cash Flow

    n/a
    		 -347.25M

    Capital Expenditures

    n/a
    		 -8.95M

    Free Cash Flow

    n/a
    		 -356.19M

    FCF Per Share

    n/a
    		 -4.33
    Full Cash Flow Statement

    Margins

    Gross margin is 65.48%, with operating and profit margins of -654.25% and -593.13%.

    Gross Margin

    n/a
    		 65.48%

    Operating Margin

    n/a
    		 -654.25%

    Pretax Margin

    n/a
    		 -593.06%

    Profit Margin

    n/a
    		 -593.13%

    EBITDA Margin

    n/a
    		 -604.51%

    EBIT Margin

    n/a
    		 -654.25%

    FCF Margin

    n/a
    		 -560.77%

    Dividends & Yields

    BEAM pays an annual dividend of $1.12, which amounts to a dividend yield of 4.8%.

    Dividend Per Share

    n/a
    		 $1.12

    Dividend Yield

    n/a
    		 4.8%

    Dividend Growth (YoY)

    n/a
    		 0%

    Payout Ratio

    n/a
    		 -24.4%

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for BEAM is $42, which is 144.6% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $42

    Price Target Difference

    n/a
    		 144.6%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 12
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 1.34

    Piotroski F-Score

    n/a
    		 3

    Add to Watchlist